Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.

Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

Keywords: Cabozantinib; Guidelines; Immune checkpoint inhibitors; Ipilimumab; Metastatic; Nivolumab; Pazopanib; Renal cell carcinoma; Sunitinib.

Publication types

  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Axitinib / administration & dosage
  • Bevacizumab / administration & dosage
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Humans
  • Ipilimumab / administration & dosage
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Nivolumab / administration & dosage
  • Sunitinib / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Ipilimumab
  • Bevacizumab
  • Nivolumab
  • atezolizumab
  • Axitinib
  • pembrolizumab
  • avelumab
  • Sunitinib